Im Cannabis Corp (IMCC)

$0.5633

+0.05

(+8.96%)▲

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Im Cannabis Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 38.10M → 10.69M (in $), with an average decrease of 71.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.20M → -3.28M (in $), with an average increase of 88.8% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 33.0% return, outperforming this stock by 52.5%

  • Vs NBIX

    In the last 3 years, Im Cannabis Corp has experienced a drawdown of -99.0%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 49.6%

Performance

  • $0.53
    $0.60
    $0.56
    downward going graph

    5.34%

    Downside

    Day's Volatility :11.65%

    Upside

    6.67%

    downward going graph
  • $0.19
    $1.43
    $0.56
    downward going graph

    66.25%

    Downside

    52 Weeks Volatility :86.78%

    Upside

    60.84%

    downward going graph

Returns

PeriodIm Cannabis CorpRussel 2000Index (Russel 2000)
3 Months
120.04%
0.0%
0.0%
6 Months
-3.05%
0.0%
0.0%
1 Year
-19.52%
-1.5%
-1.5%
3 Years
-98.97%
-21.8%
-21.8%

Highlights

Market Capitalization
6.9M
Book Value
$1.08
Earnings Per Share (EPS)
-0.54
Wall Street Target Price
0.99
Profit Margin
-19.46%
Operating Margin TTM
-48.28%
Return On Assets TTM
-13.9%
Return On Equity TTM
-54.55%
Revenue TTM
48.8M
Revenue Per Share TTM
3.81
Quarterly Revenue Growth YOY
-26.0%
Gross Profit TTM
9.2M
EBITDA
-9.8M
Diluted Eps TTM
-0.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.69
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Im Cannabis Corp(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 75.75%

Current $0.56
Target $0.99

Company Financials

FY18Y/Y Change
Revenue
3.8M
-
Net Income
1.2M
↓ 1446.72%
Net Profit Margin
32.38%
-
FY19Y/Y Change
Revenue
6.9M
↑ 74.6%
Net Income
-5.7M
↓ 540.82%
Net Profit Margin
-81.76%
↓ 114.14%
FY20Y/Y Change
Revenue
12.5M
↑ 75.12%
Net Income
-22.5M
↑ 287.3%
Net Profit Margin
-180.83%
↓ 99.07%
FY21Y/Y Change
Revenue
42.6M
↑ 241.72%
Net Income
-14.5M
↓ 35.55%
Net Profit Margin
-34.1%
↑ 146.73%
FY22Y/Y Change
Revenue
40.1M
↑ 0.06%
Net Income
-18.4M
↑ 34.58%
Net Profit Margin
-45.87%
↓ 11.77%
FY23Y/Y Change
Revenue
48.8M
↓ 10.18%
Net Income
-9.5M
↓ 61.89%
Net Profit Margin
-19.46%
↑ 26.41%
Q3 FY22Q/Q Change
Revenue
10.4M
↓ 40.51%
Net Income
-3.3M
↓ 76.12%
Net Profit Margin
-31.98%
↑ 47.69%
Q4 FY22Q/Q Change
Revenue
9.7M
↓ 7.04%
Net Income
31.8K
↓ 100.95%
Net Profit Margin
0.33%
↑ 32.31%
Q1 FY23Q/Q Change
Revenue
9.7M
↑ 0.0%
Net Income
31.8K
↑ 0.0%
Net Profit Margin
0.33%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
10.0M
↑ 0.26%
Net Income
-2.8M
↓ 8718.6%
Net Profit Margin
-28.06%
↓ 28.39%
Q3 FY23Q/Q Change
Revenue
38.1M
↑ 188.53%
Net Income
-6.2M
↑ 67.54%
Net Profit Margin
-16.29%
↑ 11.77%
Q4 FY23Q/Q Change
Revenue
10.7M
↓ 71.93%
Net Income
-3.3M
↓ 47.03%
Net Profit Margin
-30.74%
↓ 14.45%
FY18Y/Y Change
Total Assets
27.2K
↑ 304.71%
Total Liabilities
184.7K
↓ 46.0%
FY19Y/Y Change
Total Assets
23.7M
↑ 83390.53%
Total Liabilities
3.7M
↑ 1801.45%
FY20Y/Y Change
Total Assets
29.9M
↑ 23.38%
Total Liabilities
20.0M
↑ 433.04%
FY21Y/Y Change
Total Assets
225.5M
↑ 653.98%
Total Liabilities
64.7M
↑ 223.23%
FY22Y/Y Change
Total Assets
44.8M
↓ 78.89%
Total Liabilities
27.2M
↓ 55.27%
FY23Y/Y Change
Total Assets
48.8M
↓ 19.55%
Total Liabilities
35.1M
↓ 4.79%
Q3 FY22Q/Q Change
Total Assets
94.4M
↓ 49.45%
Total Liabilities
53.5M
↓ 3.52%
Q4 FY22Q/Q Change
Total Assets
41.9M
↓ 56.0%
Total Liabilities
23.8M
↓ 55.89%
Q1 FY23Q/Q Change
Total Assets
42.0M
↑ 0.0%
Total Liabilities
23.8M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
42.1M
↓ 1.83%
Total Liabilities
25.8M
↑ 6.12%
Q3 FY23Q/Q Change
Total Assets
52.4M
↓ 6.07%
Total Liabilities
32.6M
↓ 4.8%
Q4 FY23Q/Q Change
Total Assets
48.8M
↓ 6.78%
Total Liabilities
35.1M
↑ 7.8%
FY18Y/Y Change
Operating Cash Flow
-34.0K
↓ 51.89%
Investing Cash Flow
-535.2K
↑ 71.13%
Financing Cash Flow
58.2K
↓ 20.77%
FY19Y/Y Change
Operating Cash Flow
-4.6M
↑ 12783.21%
Investing Cash Flow
-2.9M
↑ 417.83%
Financing Cash Flow
13.1M
↑ 21420.89%
FY20Y/Y Change
Operating Cash Flow
-6.2M
↑ 32.89%
Investing Cash Flow
-3.2M
↑ 7.95%
Financing Cash Flow
5.3M
↓ 60.47%
FY21Y/Y Change
Operating Cash Flow
-27.0M
↑ 334.04%
Investing Cash Flow
-7.1M
↑ 121.15%
Financing Cash Flow
38.2M
↑ 623.01%
FY22Y/Y Change
Operating Cash Flow
-9.3M
↓ 63.23%
Investing Cash Flow
-1.0M
↓ 84.38%
Financing Cash Flow
3.5M
↓ 90.23%
Q3 FY22Q/Q Change
Operating Cash Flow
590.2K
↓ 154.27%
Investing Cash Flow
-136.8K
↓ 39.09%
Financing Cash Flow
-3.1M
↓ 339.65%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.5M
↓ 851.05%
Investing Cash Flow
-429.9K
↑ 211.23%
Financing Cash Flow
4.8M
↓ 255.64%

Technicals Summary

Sell

Neutral

Buy

Im Cannabis Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Im Cannabis Corp
Im Cannabis Corp
76.36%
-3.05%
-19.52%
-98.97%
-99.4%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.45%
18.72%
28.45%
40.46%
69.87%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.12%
-1.82%
-7.31%
9.45%
9.45%
Zoetis Inc.
Zoetis Inc.
-10.98%
-10.38%
-12.9%
-9.61%
53.43%
Viatris Inc.
Viatris Inc.
-5.61%
18.46%
12.35%
-16.23%
-32.07%
Catalent, Inc.
Catalent, Inc.
0.0%
24.33%
32.98%
-48.49%
27.27%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Im Cannabis Corp
Im Cannabis Corp
NA
NA
NA
-0.69
-0.55
-0.14
NA
1.08
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.84
53.84
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.93
28.93
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.48
29.48
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
222.4
222.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Im Cannabis Corp
Im Cannabis Corp
Buy
$6.9M
-99.4%
NA
-19.46%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.4B
69.87%
53.84
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.0B
9.45%
28.93
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.5B
53.43%
29.48
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-32.07%
222.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
27.27%
211.02
-31.77%

Institutional Holdings

  • Lynwood Capital Management Inc.

    4.85%

  • Black Maple Capital Management LP

    3.06%

  • AdvisorShares Investments, LLC

    1.72%

  • Bank of Montreal

    0.56%

  • BMO Capital Markets Corp.

    0.56%

  • Renaissance Technologies Corp

    0.29%

Corporate Announcements

  • Im Cannabis Corp Earnings

    Im Cannabis Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

premium medical cannabis products for global consumers – im cannabis (imc) is one of the world's pioneering medical-grade cannabis companies, with operations in israel, across europe, and canada. over the past decade, imc has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as 'roma', 'tel aviv' and 'london'. in europe, imc has established a fully operational, vertically integrated medical cannabis business, spearheaded by its eu-gmp certified distribution arm in germany and augmented by strategic alliances with certified pan-eugmp certified suppliers. to this end, imc has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. imc further intends to leverage its expertise in israel in order to bolster its res

Organization
Im Cannabis Corp
Employees
95
CEO
Mr. Marc Lustig M.B.A., M.Sc.
Industry
Healthcare

Discover More

FAQs